Cellebrite price target raised to $15 from $14 at JPMorgan

JPMorgan raised the firm’s price target on Cellebrite to $15 from $14 and keeps an Overweight rating on the shares ahead of the Q2 report on August 15. The analyst expects positive results and “healthy traction” with a subscription conversion cycle ahead. Cellebrite remains well positioned as its growth continues to accelerate amid ongoing platform expansion, deeper government penetration and migration to an upgraded subscription platform, the analyst tells investors in a research note.